The FDA has granted Fast Track designation for GLPG1972/S201086 for the treatment of patients with osteoarthritis.
The researchers found that use of trazodone correlated with similar rates of falls or major osteoporotic fractures compared with use of atypical antipsychotics.
The researchers found that from 2012 to 2017, there was an increase in the use of yoga (from 3.1 to 8.4%) and meditation (from 0.6 to 5.4%) during the previous 12 months. In 2017, girls were more likely than boys to have used yoga in the previous 12 months.
Clinical improvements during treatment with TNF-α inhibitors was comparable between men and women with ankylosing spondylitis.
Researchers assessed the effect of replacing time not walking with walking at very-light, light, or moderate-to-vigorous intensities on the risk for TKA over 5 years.
The researchers found that a fragility fracture occurred in 190 women in the placebo group and 122 women in the zoledronate group (hazard ratio [HR] with zoledronate, 0.63).
The researchers found that a larger proportion of cases than controls had prior PPI use (70 vs 63%) or histamine-2 receptor antagonist use (25 vs 23%).
Patients with axial spondyloarthritis who have inflammatory back pain or neuropathic pain may have higher pain intensity, pain interference, disease activity, and greater functional limitation compared with individuals with axial spondyloarthritis but without either comorbidity.
For patients receiving both treatments, the group receiving opioids first had mean hip-related downstream costs that were significantly higher than the group receiving physical therapy first ($18,806 versus $16,955).
Cumulative 30-day in-hospital mortality was 4.9 and 6.9% among patients who were surgically treated on admission day and those who had surgery done after day 3.
The researchers found that the overall incident delirium risk was 36.5%; 39 vs 34%, respectively, in the heavier and lighter sedation groups (P=.46).
The hospital preference instrumental variable had a stronger association with treatment than the other 3 instrumental variables (specialist access, calendar year, and geographic variation) during the effectiveness analyses.
The researchers found that in the pooled analysis, bone fracture AEs were reported in 119 of 4221 patients (2.8%) randomized to empagliflozin 10mg, 105 of 4,196 patients (2.5%) randomized to empagliflozin 25mg, and 123 of 4203 patients (2.9%) randomized to the placebo group.
Evenity is a bone-forming monoclonal antibody designed to inhibit the activity of sclerostin, which allows the drug to rapidly increase bone formation and reduce bone resorption simultaneously.
Based on these findings, the USPSTF recommends screening for women aged 65 years and older and in younger women who have been through menopause and are at increased risk.
The male patient presented in 2009 with a "3-year history of multiple interconnecting comedones in the axilla and inguinal regions, as well as scarring from previous lesions."
The researchers found that frequent HED was associated with decreased vertebral bone mineral density (BMD), even when controlling for variables most commonly associated with bone health such as lean body mass, physical activity, age at menarche, smoking, and oral contraception use.
According to the authors, this is the first study to identify medications most commonly reported for a specific adverse reaction using this database.
OsteoDetect is a computer-aided detection and diagnostic software that uses an algorithm to analyze 2-D wrist radiographs for signs of distal radius fracture.
The efficacy and safety of Prolia in the treatment of patients with glucocorticoid-induced osteoporosis was assessed in the 12-month primary analysis of a 2-year, randomized, multicenter, double-blind, parallel-group, active-controlled study (N=795).
In this multicenter, double-blind, placebo-controlled trial, patients (N=409) were randomized 1:1:1 to a postoperative regimen of IV tramadol 50mg, IV tramadol 25mg, or placebo administered over 15 minutes at hours 0, 2, 4, and once every 4 hours thereafter (up to 13 doses).
Using a privately-insured administrative database, researchers examined a total of 78,704 patients with autoimmune or inflammatory disease diagnoses between 2006 and 2015.
There was a significant correlation for anxiety levels with age, menopausal age, years since menopause, and depressive symptoms; multiple regression analysis predicted reduced BMD in the lumbar spine.
Researchers found that a non-immunosuppressant drug originally designed to treat osteoporosis (WAY-316606) targeted the same mechanism by antagonizing SFRP1, and after treating hair follicles with WAY-316606 for 6 days, the authors found enhanced human hair growth.
The researchers found that 15.4% of the patients developed a fracture during follow-up. Yearly fracture incidence varied from 3.7 to 9.9%, peaking during years four and five at 9.9 and 9.8%, respectively.
"Percutaneous vertebroplasty did not result in statistically significantly greater pain relief than a sham procedure during 12 months' follow-up among patients with acute osteoporotic vertebral compression fractures," the authors write.
Crysvita, a recombinant fully human monoclonal IgG1 antibody, works by blocking fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses vitamin D production by the kidney.
The researchers found that intervention patients reported lower numeric rating scale pain scores on ambulation than the control group on postoperative day (POD) one (1.7 versus 5.0; P <.001).